---
title: "Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (688076.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688076.SH.md"
symbol: "688076.SH"
name: "Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-06-10T08:29:04.008Z"
locales:
  - [en](https://longbridge.com/en/quote/688076.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688076.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688076.SH.md)
---

# Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (688076.SH)

## Company Overview

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.sinopep.com.cn](https://www.sinopep.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-10T04:30:12.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 102 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.21% |  |
| Net Profit YoY | -38.08% |  |
| P/B Ratio | 2.96 |  |
| Dividend Ratio | 2.02% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8918457912.54 |  |
| Revenue | 1932124354.11 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 10.24% | B |
| Profit Margin | 15.74% | A |
| Gross Margin | 61.97% | A |
| Revenue YoY | 5.21% | C |
| Net Profit YoY | -38.08% | D |
| Total Assets YoY | 25.31% | A |
| Net Assets YoY | 10.35% | B |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | 5.21% | C |
| Turnover | 0.32 | D |
| Gearing Ratio | 54.09% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5.21%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-38.08%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.96",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.02%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8918457912.54",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1932124354.11",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "10.24%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "15.74%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "61.97%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "5.21%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-38.08%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "25.31%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.35%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "5.21%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.32",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "54.09%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 28.81 | 77/222 | 28.67 | 24.50 | 21.58 |
| PB | 2.96 | 149/222 | 4.61 | 3.89 | 3.16 |
| PS (TTM) | 4.62 | 132/222 | 7.06 | 6.33 | 5.15 |
| Dividend Yield | 2.02% | 75/222 | 1.84% | 1.54% | 1.44% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-17T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.73 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688076.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688076.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688076.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688076.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**